Silence Therapeutics — Third Quarter 2026 Earnings Summary

Financial Performance:

• Revenue for the three months ended September 30, 2026, was $0, compared to $159,000 in the same period of 2025.
• Net loss for the three months ended September 30, 2026, was $12.4 million ($0.08 per share), a decrease from $21.0 million ($0.15 per share) in the prior year period.
• Research and development expenses for the quarter were $9.3 million, down from $20.5 million in the prior year, attributed to the completion of zerlasiran Phase 3 readiness and reduced personnel costs.
• General and administrative expenses for the quarter were $4.9 million, down from $5.8 million in the prior year, due to efforts to reduce administrative costs.
• Cash and cash equivalents totaled $247.7 million as of September 30, 2026, including $201.3 million in gross proceeds from an upsized public offering announced on August 11, 2026.
• Total assets were $281.5 million as of September 30, 2026, compared to $131.4 million as of December 31, 2025.
• Total shareholders' equity was a deficit of $215.0 million as of September 30, 2026, compared to a deficit of $62.3 million as of December 31, 2025.
• Weighted average shares outstanding for the quarter were 165,600,827, compared to 141,701,848 in the prior year period.
• Total outstanding shares were 186,609,073 as of September 30, 2026.

Other Key Points:

• On October 19, 2026, Silence Therapeutics entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, with the transaction expected to close in the first quarter of 2027, subject to customary closing conditions.
• On August 10, 2026, the company reported positive topline results from its Phase 2 SANRECO trial of divesiran (an investigational siRNA therapy targeting TMPRSS6) in polycythemia vera, supporting a best-in-class profile with once-every-three-month dosing.
• SANRECO Phase 2 results have been accepted for oral presentation at the American Society of Hematology (ASH) 2026 Annual Meeting, scheduled for December 12-15, 2026, in New Orleans, LA.
• The press release serves as solicitation material for the proposed acquisition and notes that a proxy statement will be filed with the SEC.
• The company's pipeline utilizes its mRNAi GOLD platform to develop siRNA therapies targeting genes associated with rare and common diseases.